



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

On October 17, 2003

TOWNSEND and TOWNSEND and CREW LLP

By: [Signature]

PATENT  
Attorney Docket No.: 015280-263110US  
Client Ref. No.: E-009-96/2  
Customer No.: 20350

RECEIVED

OCT 23 2003

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

KELLY, Kathleen

Application No.: 10/059,506

Filed: January 29, 2002

For: METHODS AND COMPOSITIONS  
FOR INHIBITING INFLAMMATION  
AND ANGIOGENESIS COMPRISING A  
MAMMALIAN CD97 ALPHA  
SUBUNIT

Confirmation No.: 7612

Examiner: Harris, Alana M.

Art Unit: 1642

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, mailed June 16, 2003, that accompanied the Examiner's Communication mailed September 17, 2003, Applicants submit that the computer-readable form in the instant application is identical with that filed in Application No. 09/284,819, filed February 11, 2000. In accordance with 37 C.F.R. § 1.821(e), please use the last filed computer-readable form filed in Application No. 09/284,819 as the computer-readable form for the instant application. A paper copy of the Sequence Listing from Application No. 09/284,819 is submitted herewith. The

information in the paper copy of the Sequence Listing is identical to that which is in the computer readable form submitted on February 11, 2000, as required under 37 C.F.R. § 1.821(f).

It is understood that the Patent and Trademark Office will make the necessary changes in application number and filing date for the computer-readable form that will be used for the instant application.

Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

**Amendments to the Specification** begin on page 3 of this paper.

**Amendments to the Drawings** begin on page 5 of this paper and include both an attached replacement sheet and an annotated sheet showing changes for Figure 3. Figures 1 and 2 are submitted herewith as formal with no changes having been made.

**Remarks** begin on page 6 of this paper.